Shares of Spero Therapeutics soared in premarket trading following GlaxoSmithKline’s announcement that it will license the company’s late-stage antibiotic asset, tebipenem HBr, a potential treatment for complicated urinary tract infections.
If you are not happy with the results below please do another search
50 search results for:
For companies that are still trying to determine what digital transformation should look like within their operations, they should look to Ireland where companies are using new and disruptive technology to transform product innovation, manufacturing operations and sustainability efforts in life sciences.
Britain’s health minister on Thursday pledged to cut waiting times for doctors’ appointments and launched a fund to support social care, in a plan that drew criticism for not doing enough to solve a staffing crisis in the National Health Service (NHS).
Uganda has confirmed seven cases of Ebola including in a man who died this week, and seven other deaths are being investigated as suspected cases of a strain for which the authorities do not yet have a vaccine, officials said on Thursday.
Rivus raised $132 million in a Series B financing round that will be used in developing HU6, a new drug class designed to treat cardio-metabolic disease by addressing obesity.
Pfizer Inc said on Thursday it would supply up to 6 million courses of its COVID-19 antiviral treatment to NGO Global Fund for low- and middle-income countries that seeks to address worldwide disparities in COVID response.
Swiss pharma giant Novartis said it would make growth in the United States its top geographic priority, even after laws were passed to rein in drug prices in the world’s largest pharmaceutical market.
The company said it plans to ask the U.S. Supreme court to uphold the validity of a patent it holds on the dosing regimen for multiple sclerosis drug Gilenya after suffering a setback in a federal appeals court ruling.
Longer-term use and early initiation of Biogen Inc.’s experimental treatment for an inherited form of amyotrophic lateral sclerosis (ALS) was effective in slowing disease progression, according to a new analysis by the company published on Wednesday.
The U.S. Centers for Disease Control and Prevention expects COVID-19 vaccine boosters targeting circulating variants of the virus to be available for children aged 5-11 years by mid-October.